Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
December 17, 2010
[Pandemic influenza vaccines. How should they be designed?]
J Löwer
Journal of Medical Virology
|
May 1, 1990
Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations
J Löwer
Arzneimittel-Forschung
|
March 1, 1988
[Gene technology in the diagnosis of viruses and vaccine development]
J Löwer
Vox Sanguinis
|
December 16, 1998
GB virus C/hepatitis G virus and intravenous immunoglobulins
C Nübling, A Gröner, J Löwer
Vaccine
|
December 12, 2001
Cold-attenuated live influenza vaccines, a risk-benefit assessment
M Pfleiderer, J Löwer, R Kurth
AIDS (London, England)
|
April 1, 1991
High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines
F Stieneker, J Kreuter, J Löwer
Biologicals : Journal of the International Association of Biological Standardization
|
February 25, 2000
Safety issues for plasma derivatives and benefit from NAT testing
H Willkommen, I Schmidt, J Löwer
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 1996
The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences
R Löwer, J Löwer, R Kurth
Journal of Virology
|
October 9, 1999
cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K
C Magin, R Löwer, J Löwer
Journal of Virology
|
January 9, 1999
Expression of the human endogenous retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1
M Knössl, R Löwer, J Löwer
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
December 17, 2010
[Pandemic influenza vaccines. How should they be designed?]
J Löwer
Journal of Medical Virology
|
May 1, 1990
Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations
J Löwer
Arzneimittel-Forschung
|
March 1, 1988
[Gene technology in the diagnosis of viruses and vaccine development]
J Löwer
Vox Sanguinis
|
December 16, 1998
GB virus C/hepatitis G virus and intravenous immunoglobulins
C Nübling, A Gröner, J Löwer
Vaccine
|
December 12, 2001
Cold-attenuated live influenza vaccines, a risk-benefit assessment
M Pfleiderer, J Löwer, R Kurth
AIDS (London, England)
|
April 1, 1991
High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines
F Stieneker, J Kreuter, J Löwer
Biologicals : Journal of the International Association of Biological Standardization
|
February 25, 2000
Safety issues for plasma derivatives and benefit from NAT testing
H Willkommen, I Schmidt, J Löwer
Proceedings of the National Academy of Sciences of the United States of America
|
May 28, 1996
The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences
R Löwer, J Löwer, R Kurth
Journal of Virology
|
October 9, 1999
cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K
C Magin, R Löwer, J Löwer
Journal of Virology
|
January 9, 1999
Expression of the human endogenous retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1
M Knössl, R Löwer, J Löwer
Page
of 5